BRCA1/2-associated and sporadic breast cancers: Fellow travelers or not?

Cancer Prevention Research

Volumn 2, Issue 2, 2009, Pages 100-103

  Garber, Judy E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA REPAIR; GENE EXPRESSION; GENE MUTATION; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HISTOLOGY; HUMAN; INTRADUCTAL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR VOLUME; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; MUTATION; NOTE; PATHOLOGY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION;

EID: 63249136588     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0243     Document Type: Review

References (32)

1. McKusick VA. On lumpers and splitters, or the nosology of genetic disease. Perspect Biol Med 1969; 12:298-312.
2. Lakhani SR, Jacquemier J, Sloane JP, et al. Multi-factorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90: 1138-1145 (Pubitemid 28380718)
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874 (Pubitemid 32878711)
4. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-548 (Pubitemid 32167867)
5. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet 2004;41:1-5.
6. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-1485 (Pubitemid 37279334)
7. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 2008;105:1680-1685 (Pubitemid 351346574)
8. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25:2273-2284
9. Martin SA, Lord CJ, Ashworth A, et al. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008;18:80-86 (Pubitemid 351694447)
10. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2008 (Epub ahead of print).
11. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002;8:571-576 (Pubitemid 35408215)
12. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-1668 (Pubitemid 39585635)
13. Bouwman P, Jonkers J. Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. Cell Cycle 2008;7: 2647-2653
14. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2008 (Epub ahead of print).
15. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921 (Pubitemid 40559006)
16. Fong P, Spicer J, Reade S. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecular inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients with advanced tumours. J Clin Oncol 2006;24: 3022.
17. De Soto JA, Deng CX. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?. Int J Med Sci 2006;3:117-123
18. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66: 8109-8115 (Pubitemid 44299177)
19. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation earners: an international case-control study. J Clin Oncol 2005;23: 7491-7496 (Pubitemid 46291812)
20. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-1337
21. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-282 (Pubitemid 47073490)
22. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other dis- ease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295: 2727-2741
23. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 2008;8:1377-1385
24. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007;13: 7357-7362
25. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003;97: 1601-1608 (Pubitemid 36350702)
26. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41-45
27. Isern AE, Loman N, Malina J, et al. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer. Eur J Surg Oncol 2008;34:1148-1154
28. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490
29. Claus EB, Petruzella S, Matloff E, et al. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 2005;293:964-969 (Pubitemid 40271128)
30. Hwang ES, McLennan JL, Moore DH, et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007;25:642-647
31. Smith KL, Adank M, Kauff N, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res 2007;13:4306-4310
32. Arun B, Vogel KJ, Lopez A, et al. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res 2009;2: 122-127